Zentalis Pharmaceuticals, Inc. ZNTL · Stock Open Zentalis Pharmaceuticals, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Zentalis Pharmaceuticals, Inc. Analysis (ZNTL)
Is Zentalis Pharmaceuticals, Inc. a good investment? Zentalis Pharmaceuticals, Inc. (ZNTL) is currently trading at 1.76 USD. Market analysts have a consensus price target of 7.44 USD. This suggests a potential upside from current levels.
Earnings Schedule: Zentalis Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is -1.77.
Investor FAQ
Does Zentalis Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -1.96.
Company Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Community Discussion